Background: In 2009, the Nepal Ministry of Health and Population launched a national program for prevention of postpartum hemorrhage (PPH) during home births that features advance distribution of misoprostol to pregnant women. In the years since, the government has scaled-up the program throughout much of the country. This paper presents findings from the first large-scale assessment of the effectiveness of the advance distribution program.
Methods: Data collection was carried out in nine districts and all three ecological zones. To assess knowledge, receipt and use of misoprostol, household interviews were conducted with 2070 women who had given birth within the past 12 months. To assess supply and provision of misoprostol, interviews were conducted with 270 Female Community Health Volunteers (FCHVs) and staff at 99 health facilities.
Results: Among recently delivered women, only 15% received information about misoprostol and 13% received misoprostol tablets in advance of delivery. Yet 87% who received advance misoprostol and delivered at home used it for PPH prevention. Among FCHVs, 96% were providing advance misoprostol for PPH prevention; however 81% had experienced at least one misoprostol stock out within the past year. About one-half of FCHVs were providing incomplete information about the use of misoprostol; in addition, many did not discuss side effects, how to recognize PPH or where to go if PPH occurs. Among health facilities, just one-half had sufficient misoprostol stock, while 95% had sufficient oxytocin stock, at the time of this assessment.
Conclusions: In Nepal, women who receive advance misoprostol are both willing and able to use the medication for PPH prevention during home births. However the supply and personnel challenges identified raise questions about scalability and impact of the program over the long-term. Further assessment is needed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460329 | PMC |
http://dx.doi.org/10.1186/s12884-017-1347-z | DOI Listing |
Turk J Obstet Gynecol
December 2024
Ankara City Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey.
Objective: To evaluate the indications and methods of termination of pregnancy (TOP) and to identify maternal complications that occur during TOP.
Materials And Methods: This retrospective study was conducted at a single tertiary center with a total of 231 patients who underwent TOP from April 2019 to March 2023. The patients were divided into two groups based on gestational age at the time of TOP and the presence of complications.
Int J Pharm Compd
December 2024
Tri-State Compounding Pharmacy, Cincinnati, Ohio.
Wound care is one of the main concerns of patients with diabetes. This case involves a 65-year-old woman with a wound (4 cm x 2 cm) on her right foot, underneath the big toe. The patient had not been successful in healing this wound using conventional preparations for a year.
View Article and Find Full Text PDFJAMA Intern Med
November 2024
Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco.
Am J Obstet Gynecol
January 2025
Department of Gynecologic Surgery and Obstetrics, Walter Reed National Military Medical Center, Bethesda, MD. Electronic address:
Objective: This study aimed to evaluate prophylactic uterotonics, antifibrinolytic medications, and vasoconstrictive agents in the prevention of hemorrhage during second-trimester abortions.
Data Sources: PubMed, Embase (Elsevier platform), Evidence-Based Medicine Reviews (Ovid platform), and Web of Science were searched from database creation to October 30, 2023.
Study Eligibility Criteria: Randomized controlled trials, cohort studies, case-control studies, and case series evaluating pregnant individuals (between 13 0/7 and 27 6/7 weeks of gestation) who underwent dilation and evacuation and received prophylactic uterotonics (methylergonovine, carboprost, oxytocin, or misoprostol), antifibrinolytic medications (tranexamic acid), or vasoconstrictive agents (vasopressin, lidocaine with epinephrine) were included in the study.
J Pediatr Adolesc Gynecol
December 2024
Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco (UCSF), Oakland, California.
Purpose: To assess young people's interest in advance provision (AP) of medication abortion-receiving mifepristone and misoprostol from a clinician in advance for their future use.
Methods: From November 2022-August 2023 we administered an electronic survey regarding advance provision to patients assigned female at birth at four Bay Area youth-serving clinics.
Results: Among 152 people ages 14-24 years (mean 17.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!